➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: March 7, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Atovaquone patents expire, and what generic alternatives are available?

Atovaquone is a drug marketed by Abhai Llc, Amneal Pharms, Apotex, Glenmark Pharms, Hetero Labs Ltd Iii, Lupin Ltd, Paddock Labs Llc, Glenmark Generics, and Mylan. and is included in nine NDAs.

The generic ingredient in ATOVAQUONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

Drug patent expirations by year for ATOVAQUONE
Drug Prices for ATOVAQUONE

See drug prices for ATOVAQUONE

Recent Clinical Trials for ATOVAQUONE

Identify potential brand extensions & 505(b)(2) entrants

NHS Research ScotlandPhase 1
National Institute for Health Research, United KingdomPhase 1
Oxford University Hospitals NHS TrustPhase 1

See all ATOVAQUONE clinical trials

Pharmacology for ATOVAQUONE
Medical Subject Heading (MeSH) Categories for ATOVAQUONE
Paragraph IV (Patent) Challenges for ATOVAQUONE
Tradename Dosage Ingredient NDA Submissiondate
MEPRON SUSPENSION;ORAL atovaquone 020500 2009-10-20

US Patents and Regulatory Information for ATOVAQUONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abhai Llc ATOVAQUONE atovaquone SUSPENSION;ORAL 210510-001 May 31, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Paddock Labs Llc ATOVAQUONE atovaquone SUSPENSION;ORAL 207833-001 Apr 28, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms ATOVAQUONE atovaquone SUSPENSION;ORAL 209685-001 Nov 21, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.